Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma
NCT07555561Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in central nervous system lymphoma (2 arms), sponsored by Beijing Boren Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 24 months. Planned start Sep 2026; status: withdrawn.
02
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT07555561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555561.